CliMB-325
CliMB-325 is an HSP90 inhibitor that can induce MHC-I (EC50 = 498 nM) expression on the surface of CT26 murine colorectal cancer cells. CliMB-325 enhances T cell activation and exhibits lower toxicity. CliMB-325 can be used for the study of colorectal cancer[1].
Product Specifications
UNSPSC
12352005
Target
HSP; MHC
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
ClC1=C2N=CN(C2=NC(N)=N1)CC3=CN(N=N3)C4=CC=C(C=C4C#N)Cl
Molecular Formula
C15H9Cl2N9
Molecular Weight
386.20
References & Citations
[1]Newkirk SE, et al. Small Molecule Modulation of MHC-I Surface Expression: A Click Chemistry-Based Discovery Approach. J Med Chem. 2025 Nov 13;68 (21) :22301-22311.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HSP90; MHC I
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS629055-01 0.05 mg
JAK1, phosphorylated (Tyr1022) (Tyrosine-protein Kinase JAK1, Janus Kinase 1, JAK-1, JAK1A, JAK1B)
Sign In for Pricing
View Details 
MBS629055-02 5x 0.05 mg
JAK1, phosphorylated (Tyr1022) (Tyrosine-protein Kinase JAK1, Janus Kinase 1, JAK-1, JAK1A, JAK1B)
Sign In for Pricing
View Details 
